Promising Treatment for ALS and Spinocerebellar Ataxia Type 2

News   Apr 25, 2017 | Original Story from the NIH

 
Antisense Oligonucleotide Shows Promise in Treatment of ALS and Spinocerebellar Ataxia Type 2
 
 
 

RELATED ARTICLES

Researchers Awarded $28M for Illuminating Druggable Genome NIH Grants

News

Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.

READ MORE

PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug Discovery

News

Investment to fund expansion of operations and progression of drug target pipeline.

READ MORE

Smaller Numbers of Dendrites Correlate With Greater Intelligence

News

The more intelligent a person, the fewer connections there are between the neurons in his cerebral cortex.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE